24 / Therapeutic Drug Monitoring
Aminoglycoside Kinetics
Individualised elimination from two measured levels
ke = ln(C₁ ÷ C₂) ÷ (t₂ − t₁) · half-life = 0.693 ÷ ke
Measured Levels
First Level (C₁) — higher, earlier
mcg/mL
Time of C₁ — after dose
h
Second Level (C₂) — lower, later
mcg/mL
Time of C₂ — after dose
h
Dosing Interval — current
h
Target Trough — for interval advice
mcg/mL
Result
—
—
Interpretation
Enter values above.
Notes & Sources
- Both levels must come from the same dosing interval, drawn after distribution is complete. A level taken during the distribution phase inflates ke and shortens the apparent half-life.
- The elimination constant is derived from the two levels themselves, so the result is specific to this patient rather than to a population estimate. That is the point of the method.
- Extrapolated values assume first-order elimination and a constant interval. They become unreliable in unstable renal function, where levels should simply be repeated.
- The suggested interval is rounded to a practical schedule. Confirm it against the target peak for the organism and the site of infection before applying it.
- Aminoglycoside targets differ substantially between conventional and extended-interval dosing, and between gentamicin, tobramycin and amikacin. Use the target that matches your regimen.